LivaNova PLC (NASDAQ:LIVN) Shares Purchased by Swiss National Bank

Swiss National Bank boosted its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 0.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 106,819 shares of the company’s stock after purchasing an additional 700 shares during the quarter. Swiss National Bank owned approximately 0.20% of LivaNova worth $4,947,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Central Pacific Bank Trust Division lifted its position in LivaNova by 21.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock valued at $191,000 after purchasing an additional 720 shares during the last quarter. Captrust Financial Advisors acquired a new stake in shares of LivaNova in the 3rd quarter worth approximately $217,000. Inceptionr LLC bought a new position in shares of LivaNova in the fourth quarter valued at approximately $217,000. Sanctuary Advisors LLC bought a new stake in LivaNova during the third quarter worth approximately $219,000. Finally, Edgestream Partners L.P. acquired a new position in shares of LivaNova during the 3rd quarter valued at $244,000. 97.64% of the stock is currently owned by institutional investors.

LivaNova Trading Up 2.3 %

Shares of NASDAQ:LIVN opened at $40.37 on Tuesday. The stock’s 50-day moving average is $45.17 and its 200-day moving average is $48.70. LivaNova PLC has a 52-week low of $36.85 and a 52-week high of $64.48. The company has a market cap of $2.19 billion, a P/E ratio of 96.12 and a beta of 1.10. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

Analyst Ratings Changes

Several research firms have recently weighed in on LIVN. Mizuho reduced their price objective on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. The Goldman Sachs Group cut their price target on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. Barclays dropped their price target on LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research report on Friday, March 7th. Stifel Nicolaus reduced their price target on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $64.00 price target on shares of LivaNova in a research note on Monday, March 17th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $61.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.